Eficacia y seguridad de la enzalutamida y docetaxel en cáncer prostático metastásico refractario

Abstract:

Background: In metastatic refractory prostate cancer (MRPC) and androgen deprivation therapy (ADT) + Docetaxel (ADT -D) is the first-line regimen, but with poor average survivals. ADT + Enzalutamide (ADT -E) is an alternative regimen with a new generation hormonal drug, but the results of its efficacy and safety in the medium have not been reported as it has recently entered the market. Objectives: To compare the efficacy and safety of ADT + enzalutamide versus ADT docetaxel in patients with MRCP. Methodology: A case-control study was carried out that non-randomly included 51 cases (live) and 89 deaths (controls) due to MRPC, treated at the Teodoro Maldonado Specialty Hospital between 01-01-2016 to 12-31-2019, which they complied with the therapeutic scheme, ECOG ≤ 2, normal bone marrow, liver and kidney function pre-treatment. Patients with liver metastases were excluded. Results: When comparing ADT-D with ADT-E, the following results were obtained: start of chemotherapy (27.6% vs 10.9%; p 0.014; OR 0.322 95% CI 0.146-0.707), increase in PSA (36.8% vs 18.8%; p 0.018; OR 0.396 95% CI 0.220-0.713), PSA value (74 ± 91 vs 21 ± 37; p 0.000), Days until PSA increase (311 ± 180 vs 477 ± 129; p 0.008), radiological progression (44.7% vs 17.2 %; p 0.001; OR 0.256 95% CI 0.142-0.464) Grade 3 adverse events (65.8% vs 36.7% p 0.015), death (82.9% vs 40.6%; p 0.000; OR 0.141 95% CI 0.103-0.193). There were no differences in overall adverse events, days to initiation of chemotherapy, or death. Conclusion: TPA-E is a safer and more effective regimen than TPA-D to treat MRCP

Año de publicación:

2022

Keywords:

• CANTÓN GUAYAQUIL
• Metástasis de la neoplasia
• Enzalutamida
• ECUADOR
• Estudios De Casos Y Controles
• Neoplasias de la próstata
• Docetaxel
• Hospital De Especialidades Dr. Teodoro Maldonado Carbo

Fuente:

rraae